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and Jan Lindemans1
Analytical and biological components of variability and
various derived indices have been determined for li-
poprotein(a) [Lp(a)], homocysteine (Hcy), cysteine (Cys),
and total antioxidant status (TAOS) in ostensibly
healthy adult Caucasians and in stable outpatients with
an increased serum Lp(a). In healthy Caucasians, aver-
age intraindividual biological CVs (CVb) were 20.0% for
Lp(a), 9.4% for Hcy, 5.9% for Cys, and 2.8% for TAOS,
CVbs being similar in men and women. In the outpa-
tient group, CVbs were comparable for Hcy, Cys, and
TAOS, but significantly lower for Lp(a) (7.5% vs 20.0%;
P <0.0001). Moreover, a significant inverse relation
between both biological and analytical CVs (CVa) and
serum Lp(a) concentrations was demonstrated. We con-
clude that average CVa and CVb values, and hence
average derived indices, are adequate for Hcy, Cys, and
TAOS, whereas individual values should be used for
Lp(a).
In addition to the traditional lipid and lipoprotein risk
factors for atherosclerotic disease, serum lipoprotein(a)
[Lp(a)], plasma homocysteine (Hcy), and serum antioxi-
dant concentrations are increasingly recognized as inde-
pendent risk factors for atherosclerosis [1–3].5 Lp(a) is a
lipoprotein particle that resembles LDL with a disulfide-
linked apolipoprotein(a) [apo(a)] side chain. Apo(a) is
structurally related to plasminogen, although it has no
plasminogen activity, and, so far, its physiological func-
tion has not been unraveled. Lp(a) is mainly synthesized
by the liver, its concentrations being mostly genetically
determined and fairly constant throughout an individu-
al’s life [1, 4, 5]. Across populations, mean and median
Lp(a) concentrations are lower in Caucasians than in
people whose ancestors originated in Africa [6] or the
Indian subcontinent [7]. However, high average concen-
trations of serum Lp(a) are observed in Caucasians with a
family history of premature ischemic heart disease [1].
Although its evolutionary conservation suggests some
selective advantage during some stage of man’s evolu-
tion, it is hypothesized that in our present condition Lp(a)
may increase the likelihood of thrombosis occurring on
atheromatous plaques, because of its plasminogen resem-
blance.
Hcy is derived from the intracellular metabolism of
methionine and is exported into plasma where it circu-
lates primarily in oxidized form (i.e., Hcy and Cys–Hcy
disulfide) and bound to proteins. Concentrations of total
Hcy are increased in 15–40% of patients with coronary,
cerebral, or peripheral arterial diseases [2, 8]. Mechanisms
that may relate to the pathogenesis of atherothrombosis in
hyperhomocyst(e)inemia are the change in hemostatic
condition from antithrombotic to thrombogenic, the in-
creased incorporation of Lp(a) into fibrin, and the in-
creased oxidation of LDL [2, 8].
The oxidation hypothesis of atherosclerotic disease
emphasizes the causal role of oxidized lipoproteins in
atherogenesis [9]. If decreased antioxidant concentrations
accelerate lipoprotein oxidation and hence atherosclerotic
disease, detection of a decreased total antioxidant status
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(TAOS), as measured by antioxidant-mediated quenching
of the absorbance of a radical cation [10], may prove to be
a valuable test.
To date, data on biological variation are absent for Hcy
(and Cys) and TAOS, and abundant but conflicting for
Lp(a) [11–19]. In the case of Lp(a), earlier estimates of the
biological intraindividual CV (CVb) showed a 7% week-
to-week variation [13], whereas in the ARIC study [14] the
CVb was estimated to be as low as 2.9%. More recent
studies [15–17] reported average CVbs of 7.6%, 10%, and
18%, whereas Marcovina et al. [18, 19] found the esti-
mated CVb to be highly variable (range 3–51%) and to
have a systematic inverse relation with the Lp(a) concen-
tration. Possibly, the highly skewed Lp(a) distribution
and the 1000-fold interindividual spread in blood Lp(a)
concentrations in Caucasians, in combination with the
investigation of rather limited numbers of individuals,
may have caused apparently conflicting data on intrain-
dividual biological variation of Lp(a).
In the present study a comprehensive biological vari-
ability study for these analytes was carried out in a rather
large group of healthy sex- and age-matched Caucasians.
To ensure inclusion of an adequate number of individuals
with high serum Lp(a), stable outpatients from the Lipid
Clinic who repeatedly had Lp(a) mass concentrations
.300 mg/L were enrolled. An experimental protocol that
minimized preanalytical and analytical sources of vari-
ability was used. The aims were: (a) to estimate, in healthy
and in chronically diseased but stable Caucasians, the
biological variation of Lp(a), Hcy, Cys, and TAOS around
the intraindividual homeostatic setpoints as well as the
relation between the biological intraindividual variation
and the analyte concentration; (b) to determine desirable
analytical goals for these new or potential risk factors on
the basis of intra- and interindividual biological variation
[11]; (c) to gain a clear understanding of the value of
conventional population-based reference values for these
analytes [12]; (d) to gain a clear insight into significant and
insignificant analyte changes in serial specimens [12, 20];
and (e) to calculate the minimum number of serial speci-
mens needed to determine the “true” analyte concentra-
tion [21].
Materials and Methods
study subjects
Healthy volunteers. Fifty-four physically healthy Cauca-
sians who had a stable life-style and diet, and who were
not on lipid-lowering medication (27 men and 27 women;
age range 21 to 46 years) were enrolled. Ongoing intake of
supplementary vitamins, minor tranquilizers, or oral con-
traceptives throughout the study period was allowed, as
well as occasional intake of an over-the-counter drug such
as aspirin or paracetamol. All subjects were free of endo-
crine, metabolic, and immune disorders. None of the
women with childbearing capability became pregnant
during the study.
Outpatients with hyper-Lp(a) lipoproteinemia. Twelve Cauca-
sian outpatients (5 men and 7 women; age range 22 to 69
years) from the Lipid Clinic of the University Hospital
Rotterdam with an Lp(a) mass .300 mg/L were included.
All patients were on a lipid-lowering diet for at least 3
months before enrollment.
study protocol
Blood was collected biweekly at each of four visits per
individual. Subjects were seen in standardized format at
each occasion, i.e., they were asked to fast for 10 to 12 h
before each visit, and to maintain their diet, life-style, and
possible medication throughout the evaluation period.
The design and intention of the study were thoroughly
explained to all subjects and informed consent was ob-
tained. All study subjects were interrogated on each of the
four visits by one of two physicians who checked, by
means of a predefined questionnaire, whether diet, life-
style, smoking and drinking habits, and possible medica-
tion were maintained throughout the study. Height and
weight were measured at the first visit, whereas body
weight was checked at each subsequent visit. Fertile
women were questioned about possible new pregnancies.
Venous blood was collected in the upright sitting
position, immediately after individuals had been seated.
Sampling was done between 0800 and 1000 by a single
phlebotomist. Whole blood was collected for Lp(a) and
TAOS [22], whereas EDTA blood was collected for Hcy
and Cys analyses [23]. Except for serum TAOS, which has
limited stability according to the manufacturer, all four
samples from one individual were analyzed in one run at
the end of the study, to omit between-run analytical
variation. The study protocol was approved by the Med-
ical Ethical Committee of the University Hospital.
specimen handling and storage
A strictly predefined protocol was used for specimen
preparation: EDTA (1.5 g/L) blood tubes were put on
crushed ice immediately after blood collection [23].
Whole-blood tubes were kept at room temperature until
clotting took place. Both whole-blood and EDTA tubes
were centrifuged at 4 °C (10 min, 1500g) within 1 h after
blood drawing [23]. Serum and EDTA plasma were sep-
arated from the cells immediately after centrifugation.
TAOS determinations were performed the same day,
whereas the other aliquots were stored at 270 °C for
combined analysis of all samples from one individual at
the end of the study. Blood specimens for this study were
gathered during a 3-month period.
lp(a), hcy, cys, and taos measurements
Lp(a) was measured in serum with an anti-apo(a) poly-
clonal capture ELISA from Biopool [TintElize lipopro-
tein(a), cat. no. 610220] [4–6]. Total Hcy and Cys were
measured in EDTA plasma by using a rapid, isocratic
HPLC method [24, 25]. Serum TAOS was applied on a
Hitachi 911 analyzer (Boehringer Mannheim) with the
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Randox kit and calibrator control material (cat. nos.
NX2332 and NX2331, respectively). The TAOS assay
measures the antioxidant-mediated quenching of the ab-
sorbance of a radical cation [10].
TAOS analyses were done in duplicate at the day of
sample collection, whereas Lp(a), Hcy, and Cys analyses
from one individual were performed in duplicate within
one run at the end of the study. The maximum sample
storage time for frozen aliquots was 5 months. To further
minimize analytical variation, a single technician per-
formed all the assays and single lots of reagents were
used. The between-run CV for the TAOS control material
was 4.3% (n 5 15 runs), corresponding to a between-run
variance of 0.0025.
statistics
If a quantity X exhibits biological variation such that the
standard deviation in an individual is proportional to the
homeostatic setpoint of the individual, then the quantity
X is said to have a constant CV. The CV is a parameter
expressing the proportionality of the standard deviation
to the homeostatic setpoint. It can be defined similarly for
the analytical variation around the true value of a speci-
men. When the CV of X is small, then it is well approxi-
mated by the standard deviation (s) of lnX, with few
assumptions required regarding the distribution of X or
lnX. A proof of this is given in the Appendix.
The smaller the CV, the better the approximation will
be. From a statistical point of view, it is better to directly
estimate the CV by estimating the s of lnX as a single
parameter (be it an approximation) than as a ratio of an
estimated standard deviation to an estimated mean. For
CVs ,0.4 (i.e., ,40%), the approximation by s of lnX is
good enough for practical purposes, considering the effi-
ciency gained by estimating it as a single parameter. In
summary, analytical CV (CVa) and CVb can be estimated
as sa and sb, respectively, after log transformation of the
measured analyte values.
Hitherto, means, variances (s2), and CVs were esti-
mated by using standard formulas. In case of TAOS, serial
specimens were analyzed in separate runs, and thus s2b
was an estimator for the total of within-subject and
between-run variance. To obtain a proper estimate of the
within-subject variance for TAOS, the between-run vari-
ance derived from the TAOS control material was sub-
tracted from s2b.
Indices were derived from CVa and CVb data
[11, 12, 20, 21, 26] as follows: analytical goal for impreci-
sion (AG CVa) #1⁄2CVb; analytical goal for bias (AG bias)
#1⁄4(CVb
2 1 CVg
2)[1/2] (CVg is the between-subject or
interindividual biological CV); index of individuality 5
(CVb
2 1 CVa
2)[1/2]/CVg; reference change value (RCV) or
critical difference 5 2.77(CVa
2 1 CVb
2)[1/2]; number of
specimens required to ensure with 95% confidence that
the mean result is within 65% of the individual’s homeo-
static setpoint [NS (65%)] 5 1.962[(CVa
2 1 CVb
2)/25];
number of specimens required to ensure with 95% confi-
dence that the mean result is within 610% of the individ-
ual’s homeostatic setpoint [NS (610%)] 5 1.962[(CVa
2 1
CVb
2)/100].
data analysis
Data analysis was done separately for healthy subjects
and outpatients after removing one sample from the
TAOS data set because of in vitro hemolysis. All analyte
results were transformed with natural logarithms. Vari-
ances calculated from the logarithmically transformed
data were multiplied by 10 000 to convert the estimated
standard deviations (s) to the CVs expressed in percent.
Differences in biological variation between men and
women in each group were tested by calculating ratios of
the pooled variance of analytical and within-subject vari-
ance from one gender to the other gender. These calcu-
lated F-ratios were compared with the critical F-values (a
5 0.05). Differences in biological variability between the
healthy subject and patient groups were calculated in a
similar way. Contribution of analytical variability to total
test variability was calculated as: {[(CVa2/CVb
2) 1 1][1/2]
2 1} 3 100% [11]. Concentration dependency of CVb and
CVa vs the average analyte concentration was studied
with linear regression analysis: lnCV 5 lna 2 b lnmean 1
residual. The null hypothesis checked was that the slope b
would be equal to zero. Confidence intervals (95%) for
serum Lp(a) were calculated as 6 1.96 [(analyte concen-
tration 3 0.01 3 CVa)
2 1 (analyte concentration 3 0.01 3
CVb)
2][1/2]/number of specimens[1/2]. Overall, a signifi-
cance level of P #0.05 was adopted.
Results
Table 1 summarizes the baseline characteristics of the
study subjects as well as the analyte concentrations at the
first visit. Mean intraindividual weight changes varied
between 20.06 and 10.98 kg between subsequent visits
(data not shown). Table 2 summarizes mean CVa, CVb,
and CVg, and percentile distributions of CVb for Lp(a),
Hcy, and Cys, whereas for TAOS only mean CVb and CVg
are presented. In outpatients, similar average CVb esti-
mates were found, except for Lp(a) (7.5% vs 20.0%; F 5
7.07; df1 5 162, df2 5 36; P ,0.0001). CVb did not differ
between men and women for any of the analytes, either in
healthy subjects (F ,1.44 at a 5 0.05; df1 5 81, df2 5 81)
or in outpatients (F ,2.18 at a 5 0.05; df1 5 15, df2 5 21
or F ,2.37 at a 5 0.05; df1 5 21, df2 5 15) (data not
shown). On the basis of average CVa and CVb values, we
found that ,10% of the total test variability was analytical
for Lp(a), Hcy, and Cys, whereas for TAOS up to 98% of
the observed test variability was analytical. Table 3 dis-
plays the average derived indices for each analyte stud-
ied. Analytical goals for imprecision, based on average
CVb, were achieved for all analytes except for TAOS
[11, 12, 26]. All analytes had marked individuality (index
,0.6) [12], demonstrating that the use of population-
based reference values is inadequate for their interpreta-
tion. In the healthy subject group average, applicable
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differences required for two results to be significantly
different at a 5 0.05 were 60% for Lp(a), 28% for Hcy, 17%
for Cys, and 9% for TAOS [20]. Further, Table 3 reveals
that for proper assessment of coronary artery disease risk
in the population by means of the assays used, multiple
serial specimens are needed if the observed value should
be within, e.g., 5% of the true value.
Concentration dependency of ln(CVa) and ln(CVb) was
studied in the healthy subject group for all analytes (data
not shown). None of the parameters showed concentra-
tion dependency, except ln[Lp(a)], the slopes being (bor-
derline) significantly different from zero (P 5 0.04 for CVa
vs subject mean per visit; P 5 0.07 for CVb vs overall
subject mean). After taking the antilogarithm the equa-
tions were: CVb 5 {[42.9/Lp(a)
0.31] 3 exp[(0.82)2/2]} and
CVa 5 {[12.2/Lp(a)
0.35] 3 exp[(0.93)2/2]}. Notable is that
the slopes were comparable, whereas the intercept with
the y-axis was 3.5 times higher for CVb compared with
CVa. Fig. 1 illustrates the impact of changing CVa and CVb
values across the Lp(a) concentration range on the Lp(a)
test variability, analyzing one, three, and five serial spec-
imens. If at least three serial specimens are analyzed per
individual, the observed Lp(a) result is within 610% of
the true value if the Lp(a) concentration is .500 mg/L.
Below 500 mg/L the test uncertainty runs up quickly
because of increasing biological and analytical CVs. If
only one specimen is analyzed, the observed Lp(a) value
is within 615–20% of the true value, even at Lp(a)
concentrations .500 mg/L. Below 500 mg/L the confi-
dence limits increase even more dramatically. At 300
Table 1. Baseline characteristics of the study subjects.
Mean 6 SD (median) or percentage Healthy participants (n 5 54) Outpatients with Lp(a) >300 mg/L (n 5 12)
Male/female ratio (%) 50/50 42/58
Smoking behavior
Nonsmokers (%) 61 58
Ex-smokers (%) 20 33
Smokers (%) 19 8
Alcohol use, no/yes (%) 19/81 0/100
Regular physical exercise, no/yes (%) 46/54 67/33
Lipid lowering medication, no/yes (%) 100/0 17/83
Age (years) 32.7 6 6.6 47.0 6 13.8
Height (cm) 174.9 6 8.7 169.0 6 9.3
Weight (kg) 74.4 6 12.4 73.5 6 14.4
Body mass index (kg/m2) 24.4 6 3.9 25.6 6 3.8
lnLp(a) (mg/L) 4.491 6 1.385 (4.411) 6.578 6 0.590 (6.686)
Homocysteine (mmol/L) 11.55 6 3.65 (10.78) 15.37 6 8.35 (13.03)
Cysteine (mmol/L) 235 6 36 (232) 260 6 32 (257)
TAOS (mmol/L) 1.334 6 0.082 (1.334) 1.245 6 0.077 (1.231)
Table 2. Overall within-run analytical and intra- and interindividual variation of Lp(a), Hcy, Cys, and TAOS in healthy
subjects and in stable outpatients with hyper-Lp(a) lipoproteinemia.
CVb, %
Parameter
Analyte conc. range
at first visit
Mean CV, % Percentiles Range Contributionof mean CVa
to total test
variation, %CVa CVb CVg 10 25 50 75 90 Min. Max.
Healthy subjects (n 5 54)
Lp(a), mg/L 2–1105 8.6 20.0 ND 1.9 6.6 10.8 23.4 30.7 0.0 58.7 8.9
Hcy, mmol/L 7.6–30.4 3.7 9.4 23.9 2.4 3.8 7.9 11.4 14.4 0.0 26.1 7.3
Cys, mmol/L 140–334 1.7 5.9 12.3 1.9 3.3 4.7 7.1 9.2 0.0 11.1 4.1
TAOS, mmol/L 1.174–1.498 4.3 2.8 4.5 — — — — — — — 97.8
Outpatients (n 5 12)
Lp(a), mg/L 201–1715 3.1 7.5 ND 1.3 3.8 6.1 9.5 13.9 1.1 14.8 8.3
Hcy, mmol/L 8.4–37.1 4.0 9.3 ND 3.1 5.7 6.3 9.9 17.0 2.9 17.9 8.8
Cys, mmol/L 214–335 2.0 6.0 12.9 1.1 2.9 5.5 8.2 9.0 0.0 9.0 5.4
TAOS, mmol/L 1.149–1.416 4.3 1.0 3.5 — — — — — — — —
ND, no data (s .0.40).
CVs were calculated from duplicate measurements at four biweekly visits, after logarithmic transformation of the analyte concentrations, Lp(a), Hcy, and Cys analyses
being performed in one run at the end of the collection period, and TAOS analyses, for reasons of limited stability, being performed at the day of sample collection,
i.e., in four different runs. For TAOS the CVa represents the between-day CV of the assay, calculated from the TAOS control material. For TAOS, only average CVb and
CVg were estimated, by correcting for the average between-day variance of the TAOS control.
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mg/L, an internationally recognized though arbitrarily
defined cutpoint for Lp(a) [1], the confidence intervals
range between 621%, 612%, and 69% depending on
whether one, three, or five serial specimens, respectively,
were analyzed.
Discussion
This study reports comprehensive data about biological
variability and certain indices derived from it for Lp(a),
Hcy, Cys, and TAOS. So far, data on biological variation
are absent for Hcy, Cys, and TAOS, and conflicting for
Lp(a) [13–19]. According to Fraser, estimates of within-
subject biological variation should be independent of (a)
the population examined, (b) the age and the number of
the subjects studied, (c) the locale where the study was
conducted, (d) the health of the subjects, (e) the time scale,
and (f) the analytical variability of the methodology used
[11, 12]. However, as a result of the wide variation of
published average CVb estimates for Lp(a), Fraser’s points
of departures do not seem to be universally valid across
different Lp(a) populations [18, 19]. Therefore we decided
to investigate biological variation both in a large random-
ized sample of healthy Caucasians and in a selected
hyper-Lp(a) lipoproteinemic patient group, enabling the
study of eventual heterogeneity of within-subject varia-
tion.
In healthy Caucasians average CVbs were 20.0% for
Lp(a), 9.4% for Hcy, 5.9% for Cys, and 2.8% for TAOS
(Table 2), mean CVbs being similar in men and women for
all analytes studied. In the outpatient group, comparable
CVb estimates were found for Hcy, Cys, and TAOS but
not for Lp(a) (7.5% in outpatients vs 20.0% in healthy
controls). Moreover, in accordance with Marcovina et al.
[18, 19], a systematic inverse relation was demonstrated
Table 3. Indices derived from biological variation data for Lp(a), Hcy, Cys, and TAOS in healthy subjects and in stable
outpatients with hyper-Lp(a) lipoproteinemia.
Parameter AG CVa, % AG bias, %
Index of
individuality RCV, %
NS
(65%)
NS
(610%)
Healthy subjects (n 5 54)
Lp(a), mg/L (10.0) ND (0.15) (60) (73) (18)
Hcy, mmol/L 4.7 6.4 0.42 28 16 4
Cys, mmol/L 2.9 3.4 0.50 17 6 1
TAOS, mmol/L 1.4 1.3 0.62 9 5 1
Outpatients (n 5 12)
Lp(a), mg/L (3.8) ND NA (23) (10) (3)
Hcy, mmol/L 4.6 ND NA 28 16 4
Cys, mmol/L 3.0 3.6 NA 18 6 2
TAOS, mmol/L 0.5 0.9 NA 5 4 1
NS (65%), NS (610%), number of serial specimens required to reduce uncertainty to within 65% and 610% of the true value, respectively; ND, no data; NA, not
applicable.
Average indices were calculated on the basis of average CVa, CVb, and CVg values, using the formulas presented in the text (Statistics). Such an approach is valid
for Hcy, Cys, and TAOS, but not for Lp(a) because of concentration dependency of CVa and CVb. Therefore, average indices derived for Lp(a) are placed in parentheses
and should be interpreted with caution.
Fig. 1. Confidence intervals (95%) for the subject’s true
value of Lp(a) as percentage of the observed serum Lp(a)
value for one, three, and five serial specimens.
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between CVa and CVb and Lp(a) concentration. For the
other analytes, no concentration dependency was found.
Our data (a) illustrate the inadequacy of using average
CVb and CVa values for Lp(a); (b) explain the controversy
in the literature regarding intraindividual biological vari-
ability of Lp(a) [13–17] and corroborate the findings of
Marcovina et al. [18, 19]; and (c) underscore the fact that
the intraindividual biological variability of Lp(a) is
greater than previously believed, especially in the low
concentration range [1].
Data on interindividual biological variation (CVg) are
presented if meaningful (Table 2). In general, interperson
variability is determined by age, sex, diet, and genetics. In
the case of Lp(a), interperson variability is mainly deter-
mined by genetics [1], whereas diet and genetics may
influence plasma Hcy concentrations [2, 8, 23]. Because
the outpatient group represents a selected high-risk
group, including individuals with both increased Lp(a)
and Hcy concentrations (Table 1), CVg data cannot be
extrapolated from one study to another. Consequently,
CVg data are specific for the population studied and
therefore are of limited value.
Several indices have been derived from the biological
variability study. First, analytical goals for imprecision,
having been the subject of a variety of approaches [11, 12],
were calculated. In this study the approach of Harris [26]
was used, which states that maximum allowable analyti-
cal imprecision should be #1⁄2CVb. Average goals for CVa
were met for Hcy and Cys, but not for TAOS (Table 3),
average goals for CVa being similar for Hcy and Cys in
either study group. In contrast, for Lp(a) a single mean
CVa goal was not ubiquitously valid because of concen-
tration dependency of the CVb estimates. From the esti-
mated regression lines that described the relation between
CVa and CVb and Lp(a) concentrations, a fairly constant
3.5-fold difference between CVa and CVb could be dem-
onstrated across the entire Lp(a) concentration range,
signifying that the imprecision of the Lp(a) Biopool kit
used is adequate at all Lp(a) concentrations. Therefore, we
disagree with Pagani and Panteghini [15, 21], who
claimed that in practice the analytical goal for Lp(a)
cannot be achieved with current assays. Notwithstanding
the lack of international Lp(a) standardization and the fact
that a different ELISA was used by these authors, the
discrepancy with their data can be explained by the
inappropriate use of average CVb and CVa estimates.
Finally, although the CVa goals were met for Lp(a) and
Hcy (and Cys), one may object that the assays were
performed under optimal conditions of variance as be-
tween-day variation was omitted. Yet between-day ana-
lytical CVs from routine practice in our laboratory of 7.1%
at 67 mg/L, 4.2% at 213 mg/L, and 5.1% at 379 mg/L
were achieved for Lp(a), whereas between-day CVs of
4.0% at 19.5 mmol/L and 3.2% at 52.2 mmol/L were
obtained for Hcy, confirming the practical attainment of
the analytical goals.
Second, desirable goals for average analytical bias were
calculated (Table 3) [11, 12]. Documenting bias of routine
assays necessitates the development of reference and (or)
definitive methods and standardization programs for the
analytes studied. So far, no international standardization
has been reached.
Third, the utility of conventional population-based
reference values was assessed by calculating an index of
individuality in the healthy subject group (Table 3). The
index gives a philosophical view on the interpretation of
analyte data measured in healthy individuals and patho-
logical changes in relation to reference intervals [12]. If the
index is ,0.6, then the use of reference intervals is of
limited value in the detection of unusual individual
results; if the index is .1.4, then reference values are of
significant utility. In this study, all analytes had marked
individuality, demonstrating that the use of population-
based reference values is inadequate for their interpreta-
tion. This favors the adoption of cutpoints based upon
relative risk of coronary artery disease.
Fourth, biological in addition to analytical variation
data are also used for the critical evaluation of the
significance of changes in results obtained from analysis
of serial specimens [12, 20]. To interpret serial results
objectively it is necessary to know the change that must
occur before significance can be claimed. This RCV de-
pends on both analytical and intraindividual biological
variation, and holds only if all individuals have the same
within-subject variation and if the analytical variation is
constant across the concentration range. For Hcy, Cys,
and TAOS, average RCVs for detecting significant
changes in 50% of the individuals are presented in Table
3. In view of the concentration dependency of CVa and
CVb for Lp(a), i.e., the observed variance reduction with
increasing Lp(a) concentrations, mean CVa and CVb can-
not be the basis for calculating the critical difference that
is generally applicable in all individuals. So far, critical
differences for Lp(a) were reported by one group [15], the
RCV being estimated as 29%, on the basis of a mean CVa
of 7.4% and a mean CVb of 7.6%. According to our
findings, critical differences for Lp(a) should be calculated
on the basis of individual CVa and CVb values.
Finally, from the variation data obtained in this study
one can estimate the number of specimens required to
determine the individual’s true homeostatic setpoint
value [21]. Again, simple recommendations regarding the
average number of specimens needed can be made for
Hcy, Cys, and TAOS (Table 3), while such an approach is
not valid for Lp(a) (Fig. 1). However, in light of the
enormous interindividual concentration differences, we
agree with Marcovina et al. [18, 19] that the CVb of Lp(a)
is not likely to be an important contributor to the misclas-
sification of an individual’s risk, unless the value is near
the cutpoint of enhanced coronary artery disease risk.
Overall, the findings in the present study demonstrate
that the understanding of the magnitude of the physio-
logical variations that occur in Lp(a), Hcy, Cys, and TAOS
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concentrations in serum or plasma is indispensable for
proper use of these laboratory data for risk classification
of patients with coronary artery disease. In essence, we
demonstrated that average CVa and CVb estimates and
mean derived indices are valid for Hcy, Cys, and TAOS,
whereas individual values should be used for Lp(a).
Second, the analytical performance of the Lp(a), Hcy, and
Cys assays used is acceptable, taking into consideration
the biological variation of these parameters, whereas the
performance of the TAOS assay was insufficient.
We are grateful to Bea van den Berg for careful planning
of the study and for doing the analytical work.
Appendix
A measured value X is supposed to have an expectation
E(X) 5 T, the unknown true value of X, and a constant
CV(X). A simple model that implies these conditions is:
X 5 TU, with U a random error term with mean E(U) 5
1 and SD(U) 5 s. This standard deviation is assumed to
be small enough (e.g., s ,0.4) that the probability of
negative or zero values of U must be zero. No further
assumptions about the distribution of U are made.
CV(X) 5 SD(X)/E(X) 5 [(Ts)/T] 5 s, which is a
constant single parameter. An approximate estimator for
s can be obtained by first taking the natural logarithm:
lnX 5 lnT 1 lnU, and then applying the so-called “delta
method” [27] to the variance of lnU:
var~lnU) < [d(lnU)/dU]2U 5 1 3 var(U)
so that var(lnU) ' s2, because [d(ln U)/dU]2 developed
for E(U) 5 1 equals unity [27]. Hence, CV(X) can approx-
imately be estimated by SD(lnX) within the same subject
or within the same specimen under very general condi-
tions.
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